@scienceinboston.comCongratulations to Dr. Joyce Liu from @danafarber.bsky.social! She is the recipient of the 2026 Michaele C. Christian Oncology Drug Development Award and Lectureship from the National Cancer Institute.
Learn more about her #CancerTherapy work: https://bit.ly/4s6iz7d
@gmj-georgia.bsky.socialA naturally occurring bacterium from amphibian intestines completely eliminated colorectal tumors in mice with a single dose—by combining di… #Cancertherapy #Colorectalcancer #Immunotherapy #Microbiome #Preclinicalresearch #Cancertherapy #Colorectalcancer #Immunotherapy #Microbiome #Preclinical…
@sigtrans-sttt.bsky.socialCan anti-BCL2 therapy achieve durable clearance of giant congenital melanocytic nevus?
BCL2 inhibition targets senescent and proliferative cells while inducing neutrophil extracellular traps and T-cell responses.
STTT #OpenAccess: doi.org/10.1038/s413...
#Apoptosis #CancerTherapy
@gmj-georgia.bsky.socialA common blood pressure drug is making cancer therapy far more powerful. Telmisartan, prescribed to millions for hypertension, enhances olaparib's anticancer … #Cancertherapy #Clinicaltrials #Drugrepurposing #Immunotherapy #Olaparib #Cancertherapy #Clinicaltrials #Drugrepurposing #Immunotherapy…
@mdpipharma.bsky.social🎯 Non-toxic #multidrug combos for RCC—rationally designed, hypoxia-enhanced. ODCs show up to 77% efficacy in 2D & 62% in 3D spheroids. Durable responses, no toxicity in organ models.
📌 doi.org/10.3390/phar...
#RCC #DrugCombinations #Hypoxia #CancerTherapy
@cancers-mdpi.bsky.social🌟We are delighted to share some highly cited #SpecialIssues in 2025 related to "Cancer Therapy" in Cancers (ISSN 2072-6694)!
🔎Explore them at the link: www.mdpi.com/journal/canc...
@cancers-mdpi.bsky.social🥳We are pleased to announce that Prof. Dr. Tadeusz Robak has been appointed as the Section Editor-in-Chief of "Cancer Therapy"!
📰Check out the short Q&A, including his vision for the journal and views on the research area and open-access publishing: www.mdpi.com/about/announ...
@bvsspa.bsky.social🧬 “Non-Canonical, Extralysosomal Activities of Lysosomal Peptidases in Physiological and Pathological Conditions: New Clinical Opportunities for Cancer Therapy” @cabimer.bsky.social.
👉 Disponible en #risalud hdl.handle.net/10668/31552
@degruyterbrillimms.bsky.social#AI could make #ProstateCancer drug delivery more precise.
This study combines PSMA-targeted, stimuli-responsive #nanocarriers with interpretable machine learning to predict targeting efficiency and optimize treatment performance.
@materchemfront.rsc.org🔔 Review article by Liyan Yang and Zhonglei Wang
Podophyllotoxin-based intelligent nanoplatforms for augmented tumor therapy: strategies, challenges, and perspectives
@mdpipharma.bsky.social🥇146 citations! #Gold #nanoparticles in #drug delivery—a comprehensive review. Synthesis, shapes, targeting, release mechanisms, cellular uptake & applications across cancer, cardiovascular, ocular & diabetes therapy.
📌 www.mdpi.com/1999-4923/16...
#AuNPs #Nanomedicine #DrugDelivery #CancerTherapy
@mdpipharma.bsky.social🎯 Carrier-free curcumin NPs + TA/Fe(III) coating = triple therapy for TNBC. Chemo + photothermal + ferroptosis in one nanodrug. High loading, NIR-triggered, 4T1 validated.
📌 www.mdpi.com/1999-4923/17...
#TNBC #Nanomedicine #Ferroptosis #CancerTherapy
@oopsmyopinion.bsky.social
@currentmedscience.bsky.social#Computational data clarify how SZKJT activates #Phytochemicals to treat OSCC. This study provides mechanistic insights into phytochemical-based #CancerTherapy. #medsky
Read: doi.org/10.1007/s115...
#currentmedicalscience #Oncology #TranslationalOncology #Phytotherapy #Cancer
